IVACC — Intervacc AB Share Price
0.000.00%
Last trade - 00:00- SEK320.36m
- SEK104.27m
- SEK11.79m
- 28
- 16
- 54
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 1.52 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.26% | ||
| Return on Equity | -25.32% | ||
| Operating Margin | -521.48% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 4.78 | 5.24 | 9.68 | 8.02 | 11.79 | 35 | 113 | -0.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Directors
- Bjorn Sjostrand CHM
- Andreas Andersson CEO
- Jan Persson CFO
- Jan-Ingmar Flock CSO
- Newton Aguiar DRC (55)
- Marianne Hansson DRC (56)
- Niels Holck DRC
- Torben Joergensen DRC (68)
- Ed Torr DRC
- Bert Urlings DRC
- Bengt Guss IND
- Stefan Stahl IND
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 22nd, 1983
- Public Since
- April 7th, 2017
- No. of Shareholders
- 14,800
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 340,813,188
- Address
- Vastertorpsvagen 135, HAGERSTEN, 129 44
- Web
- https://intervacc.se/
- Phone
- +46 812010600
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for IVACC
Q3 2025 Intervacc AB Earnings Release
Similar to IVACC
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Intervacc AB share price?
As of Today at 21:20 UTC, shares in Intervacc AB are trading at SEK0.94. This share price information is delayed by 15 minutes.
How has the Intervacc AB share price performed this year?
Shares in Intervacc AB last closed at SEK0.94 and the price had moved by -66.18% over the past 365 days. In terms of relative price strength the Intervacc AB share price has underperformed the FTSE Global All Cap Index by -68.08% over the past year.
What are the analyst and broker recommendations for Intervacc AB?
The overall consensus recommendation for Intervacc AB is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Intervacc AB dividend yield?
Intervacc AB does not currently pay a dividend.
Does Intervacc AB pay a dividend?
Intervacc AB does not currently pay a dividend.
When does Intervacc AB next pay dividends?
Intervacc AB does not currently pay a dividend.
How do I buy Intervacc AB shares?
To buy shares in Intervacc AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Intervacc AB?
As of the previous close price of SEK0.94, shares in Intervacc AB had a market capitalisation of SEK320.36m.
Where are Intervacc AB shares listed?
Here are the trading details for Intervacc AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: IVACC
What kind of share is Intervacc AB?
Based on an overall assessment of its quality, value and momentum Intervacc AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Intervacc AB share price forecast for 2025?
The analyst consensus target price for shares in Intervacc AB is SEK6.86. That is 629.79% above the last closing price of SEK0.94.
Analysts covering Intervacc AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.69 for the next financial year.
Find out moreWhat is the trend in the Intervacc AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intervacc AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +4.71%.
As of the last closing price of SEK0.94, shares in Intervacc AB were trading -39.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Intervacc AB PE Ratio?
The Intervacc AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Intervacc AB?
Intervacc AB's management team is headed by:
- Bjorn Sjostrand - CHM
- Andreas Andersson - CEO
- Jan Persson - CFO
- Jan-Ingmar Flock - CSO
- Newton Aguiar - DRC
- Marianne Hansson - DRC
- Niels Holck - DRC
- Torben Joergensen - DRC
- Ed Torr - DRC
- Bert Urlings - DRC
- Bengt Guss - IND
- Stefan Stahl - IND